secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001437749-23-022345
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics appoints Thomas Anderson to board; Matthew Plooster resigns
------------------------------------------------------------------------------

- Thomas Anderson appointed Class III director effective August 7, 2023; term expires at 2024 annual meeting.
- Anderson is CEO of SwanBio Therapeutics and former chief commercial strategy officer at Sage Therapeutics.
- Anderson receives initial option for 58,800 shares vesting over 3 years and $40,000 annual retainer.
- Matthew R. Plooster resigned from the board effective immediately upon Anderson's appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923022345/0001437749-23-022345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923022345/zvra20230807c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-022345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer